MerckMRK
- Legal name
- Merck & Co., Inc.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- NYSE
Stock Price $MRK
Latest filings
You are here#4 of 59 in Healthcare by market cap
Area = market cap · hover a tile to read it
MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 88 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 3, 2016
- 10-K · Feb 26, 2016
- 8-K · May 5, 2016
- 10-Q · May 9, 2016
- 8-K · May 27, 2016
- 8-K · Jul 29, 2016
- 10-Q · Aug 8, 2016
- 8-K · Oct 25, 2016
- 8-K · Nov 2, 2016
- 10-Q · Nov 7, 2016
- 8-K · Feb 2, 2017
- 8-K · Feb 23, 2017
- 10-K · Feb 28, 2017
- 8-K · May 2, 2017
- 10-Q · May 9, 2017
- 8-K · May 25, 2017
- 8-K · Jul 28, 2017
- 10-Q · Aug 8, 2017
- 8-K · Oct 27, 2017
- 8-K · Nov 6, 2017
- 10-Q · Nov 7, 2017
- 8-K · Jan 26, 2018
- 8-K · Feb 2, 2018
- 8-K · Feb 26, 2018
- 10-K · Feb 27, 2018
- 8-K · May 1, 2018
- 10-Q · May 8, 2018
- 8-K · May 24, 2018
- 8-K · Jul 27, 2018
- 10-Q · Aug 7, 2018
- 8-K · Sep 27, 2018
- 8-K · Oct 4, 2018
- 8-K · Oct 25, 2018
- 10-Q · Nov 6, 2018
- 8-K · Dec 10, 2018
- 8-K · Jan 30, 2019
- 8-K/A · Feb 1, 2019
- 8-K · Feb 1, 2019
- 10-K · Feb 27, 2019
- 8-K · Mar 7, 2019
- 8-K · Apr 30, 2019
- 10-Q · May 8, 2019
- 8-K · May 31, 2019
- 8-K · Jul 30, 2019
- 10-Q · Aug 6, 2019
- 8-K · Oct 29, 2019
- 10-Q · Nov 5, 2019
- 8-K · Jan 31, 2020
- 8-K · Feb 5, 2020
- 10-K · Feb 26, 2020
- 8-K · Apr 28, 2020
- 10-Q · May 6, 2020
- 8-K · May 29, 2020
- 8-K · Jun 24, 2020
- 8-K · Jul 31, 2020
- 10-Q · Aug 5, 2020
- 8-K · Oct 27, 2020
- 10-Q · Nov 5, 2020
- 8-K · Feb 1, 2021
- 8-K · Feb 4, 2021
- 8-K · Feb 4, 2021
- 10-K · Feb 25, 2021
- 8-K · Mar 24, 2021
- 8-K · Mar 26, 2021
- 8-K · Apr 29, 2021
- 8-K · May 5, 2021
- 10-Q · May 5, 2021
- 8-K · May 27, 2021
- 8-K · Jun 3, 2021
- 8-K · Jun 21, 2021
- 8-K · Jul 29, 2021
- 10-Q · Aug 9, 2021
- 8-K · Aug 20, 2021
- 8-K · Oct 28, 2021
- 10-Q · Nov 5, 2021
- 8-K · Dec 10, 2021
- 8-K · Feb 3, 2022
- 10-K · Feb 25, 2022
- 8-K · Mar 25, 2022
- 8-K · Apr 21, 2022
- 8-K · Apr 28, 2022
- 10-Q · May 5, 2022
- 8-K · May 26, 2022
- 8-K · Jul 28, 2022
- 10-Q · Aug 5, 2022
- 8-K · Oct 27, 2022
- 10-Q · Nov 3, 2022
- 8-K · Feb 2, 2023
- 10-K · Feb 24, 2023
- 8-K · Apr 27, 2023
- 10-Q · May 5, 2023
- 8-K · May 17, 2023
- 8-K · May 26, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 7, 2023
- 8-K · Oct 26, 2023
- 10-Q · Nov 3, 2023
- 8-K · Nov 28, 2023
- 8-K · Feb 1, 2024
- 8-K · Feb 20, 2024
- 10-K · Feb 26, 2024
- 10-K/A · Apr 11, 2024
- 8-K · Apr 25, 2024
- 10-Q · May 3, 2024
- 8-K · May 30, 2024
- 8-K · Jul 30, 2024
- 10-Q · Aug 5, 2024
- 8-K · Oct 31, 2024
- 10-Q · Nov 6, 2024
- 8-K · Nov 22, 2024
- 8-K · Feb 4, 2025
- 10-K · Feb 25, 2025
- 8-K · Apr 24, 2025
- 10-Q · May 2, 2025
- 8-K · May 29, 2025
- 8-K · Jul 29, 2025
- 10-Q · Aug 5, 2025
- 8-K · Sep 9, 2025
- 8-K · Oct 30, 2025
- 10-Q · Nov 5, 2025
- 8-K · Dec 4, 2025
- 8-K · Feb 3, 2026
- 10-K · Feb 24, 2026
- 8-K · Apr 30, 2026
- 10-Q · May 4, 2026
- 8-K · May 22, 2026
- 8-K · May 28, 2026
- 8-K · Aug 4, 2026
- 10-Q · Aug 7, 2026
- 8-K · Oct 13, 2026
- 8-K · Oct 29, 2026
- 10-Q · Nov 4, 2026
- 8-K · Nov 18, 2026
01—Key figures
Revenue Trend
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025
- $65.01B
1 older move runs past ±25% (largest +67.7%); point at, tap or drag across the bars to read one.
Latest bar from 10-KFY2025Click a bar to open its SEC filingTap a bar to open its SEC filing
View full history →All MRK Financial Metrics60 metrics
Income Statement15
Balance Sheet25
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Receivables
- Inventory
- Prepaid & Other
- PP&E
- Goodwill
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Short-Term Debt
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Treasury Stock
- NCI
- Total L&E
Cash Flow15
02—Overview
Merck Financial Overview 2021–2025
Updated Nov 5, 2026Merck’s flagship oncology drug Keytruda generated a staggering $31.7 billiona in FY2025, single-handedly accounting for nearly 50% of total sales. This immense cash generation underscores a high-stakes investment thesis: Merck is a cash-rich oncology powerhouse urgently deploying capital into massive pipeline acquisitions to offset severe revenue concentration before its primary asset faces government price negotiations in 2029.
The top line has expanded reliably over the last half-decade, as total revenue grew from $48.7 billion in FY2021 to $65.0 billionb in FY2025. Over that window, Keytruda sales nearly doubled from $17.2 billion, providing an unparalleled growth engine. However, the wider portfolio faces acute friction. Gardasil vaccine sales collapsed 39% in FY2025 due to deteriorating demand and inventory issues in China. To diversify away from these headwinds, management has executed aggressive buyout sprees, including the $10.5 billion purchase of Verona Pharma. These heavy research and development expenses have repeatedly distorted profitability, dragging reported earnings down to just $0.14 per share in FY2023 due to massive acquisition charges.
At the close of FY2025, the stock traded at $105.26c. Merck’s financial trajectory now hinges on executing a newly announced $3.0 billion restructuring program aimed at generating $1.7 billion in annual savings by 2027, streamlining operations to bridge the gap between its current blockbusters and a newly acquired respiratory and immunology pipeline.
Recent Developments (Q2 and Q3 2026)
Merck posted $50.98 billiond in total sales for the first nine months of 2026, marking a 5% increase year-over-year. Despite top-line momentum driven by WINREVAIR surging 93% to $694 million in the third quarter, profitability experienced severe compression. The company absorbed a net loss of $510 million over the nine-month period, dragged down by massive research and development charges from acquiring Cidara Therapeutics and Terns Pharmaceuticals. Consequently, management revised full-year 2026 non-GAAP earnings guidance down to a range of $2.77 to $2.82 per share, while lifting sales expectations to $66.8 billion through $67.3 billion.
The bull case highlights robust demand for non-oncology growth drivers like WINREVAIR and strong operating cash flow totaling $15.8 billione. Conversely, the bear case centers on heavy acquisition-driven dilution and looming pricing threats from the Inflation Reduction Act. Trading at a price-to-earnings ratio of 20.7x based on annual earnings of $7.28 as of the Q3 2026 filing, the stock reflects a balanced valuation between pipeline promise and near-term margin headwinds.
What to watch: Integration progress of acquired respiratory and infectious disease assets; ongoing regulatory decisions regarding pipeline candidates.
03—Filings
Recent SEC Filings
- 8-KMerck 8-K Report, Executive Changes (Nov 18, 2026)This 8-K filing from Merck & Co., Inc. (MRK) primarily announces changes within its Board of Directors. Long-serving board member Thomas H. Glocer has notified the Company of his intention to retire from the Board at the 2027 Annual Meeting of Shareholders. This transition is not attributed to any disagreements with the Company's operations or policies. Concurrently, the independent members of the Board have appointed Douglas M. Baker, Jr. as the new independent lead director, effective January 1, 2027, succeeding Mr. Glocer in this capacity. Mr. Baker brings extensive experience in corporate governance, global marketing, sales, and operations from his previous role as CEO of Ecolab Inc. This leadership transition within the Board is a key focus of this report for investors.
- 8-KMerck 8-K Report, Financial Results (Oct 29, 2026)Merck & Co., Inc. (MRK) reported strong third-quarter 2026 financial results, driven by continued robust sales growth in its oncology and animal health segments, alongside contributions from other key products like WINREVAIR. Total worldwide sales reached $18.1 billion, a 5% increase year-over-year, with KEYTRUDA and KEYTRUDA QLEX sales showing a significant 6% rise to $8.6 billion. WINREVAIR demonstrated exceptional growth, soaring by 93% to $694 million. The company also highlighted substantial progress in its diverse pipeline, particularly in oncology, with key data presentations at the ESMO Congress 2026 and regulatory milestones such as the U.S. FDA's acceptance of a priority review for sacituzumab tirumotecan (sac-TMT) in endometrial cancer. Merck has narrowed and raised its full-year 2026 financial outlook, now expecting sales between $66.8 billion and $67.3 billion and non-GAAP EPS between $2.77 and $2.82, reflecting confidence in its ongoing growth trajectory and pipeline advancements.
- 8-KMerck 8-K Report, Executive Changes (Oct 13, 2026)Merck & Co., Inc. (NYSE: MRK) filed a Form 8-K on October 13, 2026 to report the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. Diaz, a managing partner at Cressey & Company and former CEO of Myriad Genetics and Kindred Healthcare, will join the Audit Committee and the Research Committee. With his addition, the board will grow to 14 members, and he will stand for shareholder election at the May 2027 annual meeting. For investors, this is a governance-level event rather than a financial one. The filing contains no earnings, guidance, financing, or material operational disclosures. The appointment of an experienced healthcare executive to the Audit Committee is a modest positive for board oversight of financial reporting and internal controls, and his seat on the Research Committee adds healthcare leadership experience to oversight of the company's pipeline. Diaz's compensation will follow Merck's standard non-employee director program, as described in the April 8, 2026 proxy statement, so no new compensation arrangement was disclosed. The company also states that Diaz has no arrangements or understandings with any other person regarding his election and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K. Overall, the filing is routine and unlikely to have a direct effect on the stock price or the company's near-term financial outlook.
- 8-KMerck 8-K Report, Financial Results (Aug 4, 2026)Merck & Co. (MRK) reported second-quarter 2026 results on August 4, 2026, with worldwide sales of $16.6 billion, up 5% (4% excluding FX). Growth was led by KEYTRUDA/KEYTRUDA QLEX ($8.4 billion, up 5%, including $463 million of initial KEYTRUDA QLEX sales), WINREVAIR ($588 million, up 75%), and Animal Health ($1.8 billion, up 8%). Gross margin compressed on a GAAP basis to 73.5% from 77.5%, and non-GAAP to 81.1% from 82.2%, reflecting higher amortization and inventory write-downs. The headline result was a GAAP loss of $0.54 per share and a non-GAAP loss of $0.13 per share, driven by a $2.31 per share (about $5.7 billion) one-time R&D charge for the acquisition of Terns Pharmaceuticals, which carried no tax benefit. The full-year 2026 sales outlook was narrowed and raised to $66.3-$67.3 billion from $65.8-$67.0 billion. Non-GAAP EPS guidance, however, fell sharply to $2.66-$2.76 from $5.04-$5.16. That reduction reflects one-time charges of $3.62 per share for the Cidara acquisition and $2.31 per share for Terns, plus about $0.12 per share of financing and MK-4208 advancement costs. The non-GAAP effective tax rate guidance rose to 35.0%-36.0% from 23.5%-24.5%, because the acquisition charges are not tax-deductible. Non-GAAP operating expenses are now guided to $42.0-$42.7 billion, up from $36.0-$36.8 billion, largely due to these one-time R&D charges. Pipeline news was substantial. The FDA approved LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, and several KEYTRUDA combination approvals were granted. The company also announced positive Phase 3 TroFuse-005 data for sac-TMT in endometrial cancer and positive ATLAS-UC data for tulisokibart, while the tulisokibart SSc-ILD study failed its primary endpoint and will be discontinued. Investors should weigh strong top-line and launch momentum against the sharp near-term EPS reset, the continued KEYTRUDA patent-cycle transition, and the ongoing cost of business development.
- 8-KMerck 8-K Report, Shareholder Vote Results (May 28, 2026)This 8-K filing from Merck & Co., Inc. (MRK) reports on the outcomes of its Annual Meeting of Shareholders held on May 26, 2026. The primary focus of the filing is the voting results on several key corporate matters. Importantly, all director nominees were elected by a substantial majority of votes cast, indicating continued shareholder confidence in the current board's leadership. Shareholders also approved the compensation of named executive officers on a non-binding advisory basis and ratified the appointment of the company's independent registered public accounting firm for 2026, with strong support for both proposals. However, the filing also highlights shareholder sentiment on ESG-related matters. Two shareholder proposals, one concerning a report on DEI risks in federal contracting and another on healthcare coverage gaps, received a very small percentage of 'FOR' votes relative to 'AGAINST' votes, suggesting limited shareholder backing for these specific initiatives at this time. Similarly, a proposal regarding political contributions also saw a significant majority vote against it. Investors should note the strong approval for governance and executive compensation matters, alongside the clear shareholder rejection of the presented ESG-focused proposals.
04—See also
Related Companies
Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.